Due to the time and effort requirements for the development of a new drug, and the high attrition rates
associated with this developmental process, there is an intense effort by academic and industrial researchers to find novel
ways for more effective drug development schemes. The first step in the discovery process of a new drug is the
identification of the lead compound. The modern research tendency is to avoid the synthesis of new molecules based on
chemical intuition, which is time and cost consuming, and instead to apply in silico rational drug design. This approach
reduces the consumables and human personnel involved in the initial steps of the drug design. In this review real
examples from our research activity aiming to discover new leads will be given for various dire warnings diseases. There
is no recipe to follow for discovering new leads. The strategy to be followed depends on the knowledge of the studied
system and the experience of the researchers. The described examples constitute successful and unsuccessful efforts and
reflect the reality which medicinal chemists have to face in drug design and development. The drug stability is also
discussed in both organic molecules and metallotherapeutics. This is an important issue in drug discovery as drug
metabolism in the body can lead to various toxic and undesired molecules.
Keywords: AT1R, AT2R, Drug design, LigandScout, MAGL, metallotherapeutics, molecular docking, olmesartan,
pharmacophore screening, virtual screening.
Rights & PermissionsPrintExport